Copy For Citation
GÜMÜŞ M., Ozgur A., Tutar L., DİŞLİ A., KOCA İ., TUTAR Y.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol.17, no.14, pp.1231-1245, 2016 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
17
Issue:
14
-
Publication Date:
2016
-
Doi Number:
10.2174/1389201017666161031105815
-
Journal Name:
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.1231-1245
-
Keywords:
Benzodiazepine, cancer, bone cancer, Hsp90, client proteins, HSP90, GELDANAMYCIN, ANGIOGENESIS, DISCOVERY, OXAZEPINE, 3-KINASE, STRATEGY
-
Yozgat Bozok University Affiliated:
Yes
Abstract
Background: Despite development of novel cancer drugs, invasive ductal breast carcinoma and its metastasis are still highly morbid. Therefore, new therapeutic approaches are being developed and Hsp90 is an important target for drug design. For this purpose, a series of benzodiazepine derivatives were designed and synthesized as novel Hsp90 inhibitor.